1940 - The Company was Incorporated as a private limited company on 23rd September and converted into public limited company on 16th Sept. 1988. The Company was promoted as a partnership firm in 1936 by Late Mr. Anand Chandavarkar for the import of pharmaceutical dosage forms, specialised infant foods and surgical goods. It was converted into a Pvt. Ltd. Company under the name Fairdeal Corporation Pvt. Ltd. in Mumbai. 1949 - A formulation unit was set up at Jogeshwari. - During the mid seventies, the Company went in for a backward integration by setting up a unit for manufacture of basic drugs at Roha. 1985 - Effective 24th June, the name of the Company was changed to FDC Pvt. Ltd. 1991 - A biotechnology based R & D division was set up at Waluj. Bulk drugs one formulated into injectables, tablets and capsules at the Jogeshwari Plant. 1993 - The Company commissioned a new unit at Waluj for manufacture of ophthalmic products using the labour from latest form/fill/seal technology. 1995 - 72,75,000 No. of equity shares issued to promoters, directors etc. 27,28,200 No. of equity shares were issued at a premium of Rs 90 per share on 29th January 1996 of which 1,00,000 shares reserved and allotted to Directors, their friends, relatives and associates. Of the remaining 15,000 shares to UTI on firm allotment. - Another 1,12,400 shares issued to employees on preferential basis (only 53,000 shares taken up). Balance 25,00,800 shares issued to the public along with 59,400 shares from employees quota (13,36,980 shares taken up). 1996 - The Company introduced for the first time a unique dosage form of ophthalmics in the form of unit dose without preservating. - A modern biotechnology Lab was set up at Jogeshwari for Research and Development. - The Company proposed to give a major thrust on computerisation by switching over from the existing modular hardware and software on to an integrated RDBMS to facilitate dissemination of information throughout the organisation. - It was also proposed to set up a communication network by acquiring VSATS for linking all existing units with Corporate Office. - Fresh capacities were proposed to be built up for bull drugs viz., cinnarizone at 500 Kgs p.a. and Floravizine at 120 kgs. per annum. - The Company undertook to technically upgrade the capacity in the ophthalmic dosages segment by installing a Form-fill-seal (FFS) machine at its plant in Waluj. - The Company undertook to set up two independent units adjacent to each other at Sinnar, Nasik for manufacture of penicillin based antibiotic formulations including sterile injectables, tablets, capsules etc. 2000 - The company has launched Reliter, a dietart supplement for people over 49 with active lifestyles. 2001 - The Rs. 150 crore FDC, best-known for its rehydration sale electral has tied up with Aspen Pharmacre to sell its ophthalmic products in South Africa. - FDC Ltd, makers of the popular Electral brand, has launched Simyl MCTOil -- a naturitional supplement for children and adults suffering from inadequate fat absorption. - The Company has launched Simyl MCT Oil, claimed to be unique nutritional supplement for children and adults suffering from inadequate fat absorption. 2002 -Ms Shalini Shenoy is appointed as the Compliance Officer of the company. 2003 - Received GMP accreditation from the Medicines Control Council (MCC) of the Republic of South Africa, for registration of Oral powders and Sterile Ophthalmic dosages. -Mr. Rohit R Chandavarkar, the Company's Wholetime Director has passed away on October 29, 2003. 2005 -FDC receives CE mark approval for its 2 products from DNV - Norway 2009 - Fdc Ltd has appointed Mr. Ameya A. Chandavarkar, as a whole time director of the Company w.e.f. November 01, 2009. 2010 -Fdc Limited have recommended a dividend of Rs.1.75/- per equity share (175%). 2011 -FDC's Ophthalmic facility at Waluj, Aurangabad continues to be approved by UK MHRA -FDC receives approval (Marketing Authorization) for Dorzolamide 2% w/v Eye Drop Solution and Dorzolamide 2% w/v & Timolol Maleate 0.5% w/v Eye Drop Solution from UKMHRA (RMS) under Decentralised Procedure. -FDC receives Certificate of Appreciation Patents award from Pharmexcil 2012 -FDC Ltd is pleased to announce that it has received its first Indian Biotech Patent for the invention entitled METHOD FOR DETERMINING THE POTENCY OF G-CSF. -Fdc Ltd has appointed Mr. Vinod G. Yennemadi as an Additional Director on the Board of the Company. 2013 - Board recommended a Final Dividend of Rs. 2.25/- per equity share (225%). - IDMA Margi Memorial Best Patent Award for BEST NEW CHEMICAL ENTITY PATENT AWARD 2012-13 - Pharmexcil Patent Award NEW CHEMICAL ENTITIES (NCEs) SILVER AWARD 2012-2013 2014 - Board recommended a Final Dividend of Rs. 2.25/- per equity share (225%). - FDC Ltd. has appointed Ms. Nomita R. Chandavarkar, as an Additional Director of the company. 2015 -FDC Ltd. - Intimation of purchase of Leasehold Property situated at Jogeshwari (East). 2016 -FDC to develop cost-effective processes for manufacture bulk drugs. -FDC receives two observations from USFDA for Waluj plant. 2020 - FDC Ltd launches two variants of Favipiravir drug for Covid-19. 2022 -FDC Limited'S Brand ZIFI And FAVENZA Awarded At AWACS 2022.